title: Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial.
abstract: This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis. A total of 479 patients diagnosed with primary chronic glomerulonephritis were recruited from outpatient clinics and were randomly assigned to the treatment group (Rehmannia glutinosa acteosides, two 200-mg capsules, bid; and irbesartan, one 150-mg tablet, qd) or the control group (irbesartan, one 150-mg tablet, qd). The primary outcome was 24-h urinary protein. Secondary outcome measures included blood pressure, estimated glomerular filtration rate, erythrocyturia, serum alanine aminotransferase, aspartate transaminase and electrolytes. After 8 weeks of treatment, the treatment group showed a mean reduction in 24-h proteinuria of 36.42% compared to baseline, which was significantly higher than the mean reduction from baseline of 27.97% in the control group (P = 0.0278).Adverse drug reactions occurred at a similarly low rate in the treatment group (0.4%) and control group (1.2%, P = 0.3724). In the treatment of chronic glomerulonephritis, the combination of Rehmannia glutinosa acteosides and irbesartan can reduce proteinuria more effectively than irbesartan alone.
authors.affiliation: Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China.
authors.forename: HongYu
authors.initials: H
authors.lastname: Qiu
authors.forename: Ping
authors.initials: P
authors.lastname: Fu
authors.forename: WenXing
authors.initials: W
authors.lastname: Fan
authors.forename: Chuan
authors.initials: C
authors.lastname: Zuo
authors.forename: Ping
authors.initials: P
authors.lastname: Feng
authors.forename: Peng
authors.initials: P
authors.lastname: Shi
authors.forename: Lina
authors.initials: L
authors.lastname: Cao
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Hui
authors.initials: H
authors.lastname: Zhong
authors.forename: ZhongPing
authors.initials: Z
authors.lastname: Gou
authors.forename: YaPing
authors.initials: Y
authors.lastname: Liang
authors.forename: Mei
authors.initials: M
authors.lastname: Shi
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy; D032267:Rehmannia / Q000737:chemistry*; D013777:Tetrazoles / Q000627:therapeutic use*; D059808:Polyphenols
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D005960:Glucosides; D000077405:Irbesartan; D010636:Phenols; D013777:Tetrazoles; C058956:acteoside; D059808:Polyphenols
keywords: Rehmannia glutinosa acteosides; Traditional Chinese Medicine; chronic disease; general acteoside in extract of Rehmanniae leaves; randomized clinical trials